Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bayer Grabs Number One Pharma MNC Spot In China From AstraZeneca

This article was originally published in PharmAsia News

Executive Summary

According to the latest figures on hospital drug usage in China, Bayer HealthCare has snatched the number one pharmaceutical MNC title in Q1 this year from previous reigning firm AstraZeneca. Pfizer retained its third spot while Roche and Sanofi-Aventis clinched the fourth and fifth positions. These five foreign pharmaceutical companies grew over 30 percent each in the quarter, with the top three exceeding 35 percent. The high growth is attributed to two factors: China's continuous improvement of its intellectual property rights protections and market regulations to meet international standards, which speeds up launches of new drugs. Another leading factor is corporate sales forces' rapid expansion and perfection of distribution networks. Analysts observe that the leading firms adopt sales strategies tailored for the local market. (Click here for more - Chinese Language)

You may also be interested in...

US COVID-19 Vaccine Adcomm: First Take-Aways

From efficacy endpoints to patient warehousing, US FDA advisors weigh in on vaccine development and regulatory review.

QUOTED. 23 October. Dan Buehner.

Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.

Gilead’s Veklury Approval Shows US FDA’s Existing Regulatory Tools Are Up To The COVID-19 Challenge

The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts